PAI-1 inhibition as anti-fibrotic therapy
PrimaryMDI's core causal theory is that plasminogen activator inhibitor-1 is a druggable driver of fibrosis and fibroproliferative disease, so an orally available PAI-1 inhibitor should reduce pathological fibrotic disease activity. The testable prediction is that patients or models with fibrotic remodeling will show reduced fibrotic progression or improved disease markers when PAI-1 activity is blocked.
Popperian evaluation
The premise is credible but still underbuilt in the supplied evidence. PAI-1 is pharmacologically tractable in vivo: MDI-2268 at 3 mg/kg reduced mouse venous thrombus weight to 5.5 +/- 1.6 mg with p = 0.016, and bleeding time did not significantly increase. That supports druggability and pathway engagement. The harder claim is causal anti-fibrotic activity. The evidence here says PAI-1 is implicated in fibrosis, but it does not show that fibrotic remodeling depends enough on PAI-1 blockade to change disease course.
Supporting evidence: The theory names a specific target, PAI-1, and a specific intervention class, orally available PAI-1 inhibition.; The MDI-2268 venous thrombosis mouse study reported reduced thrombus weight at 3 mg/kg without significant prolongation of bleeding time.; The causal chain is internally coherent: if PAI-1 drives fibroproliferative remodeling, blocking PAI-1 should reduce fibrotic activity.
Counter evidence: The supplied positive in vivo study is an acute venous thrombosis model, not a fibrosis model.; The bridge from pro-fibrinolytic or anti-thrombotic activity to anti-fibrotic efficacy is an assumption with low confidence in the reasoning graph.; Several listed publications are unrelated to PAI-1, fibrosis, or MDI-2268, so they add no support.
The theory explains one observed fact well: PAI-1 inhibition can produce measurable biology in vivo. It does not yet explain anti-fibrotic outcomes, because the supplied evidence has not shown those outcomes. An alternative explanation fits the current evidence cleanly: MDI-2268 is acting as a pro-fibrinolytic, anti-thrombotic agent in an acute clot model, while its relevance to chronic fibrotic remodeling remains unproven.
Supporting evidence: MDI-2268 reduced thrombus weight in the mouse venous thrombosis model, which is consistent with pharmacologic PAI-1 inhibition.; The lack of significant bleeding-time prolongation supports a potentially usable therapeutic window in that model.
Counter evidence: No supplied study reports reduced collagen deposition, improved tissue stiffness, histologic fibrosis scores, lung function, liver fibrosis markers, or kidney fibrosis markers after PAI-1 inhibition.; The observed thrombus-weight effect can be explained by enhanced fibrinolysis without invoking a disease-modifying anti-fibrotic mechanism.; Unrelated publications on sarcopenia, AI laboratory checklists, and dietary restriction do not explain or support the PAI-1 fibrosis theory.
The theory is testable in a strong Popperian sense. It predicts that blocking PAI-1 in fibrotic remodeling should reduce fibrotic progression or improve disease markers. That can fail plainly in animal models or patients: if target engagement is shown but fibrosis endpoints do not move, the core causal claim takes a direct hit.
Supporting evidence: The stated prediction names the tested condition, fibrotic remodeling, the intervention, PAI-1 blockade, and the expected result, reduced progression or improved markers.; Direct anti-fibrotic tests could use fibrosis progression, histology, imaging, or disease-marker endpoints.; The theory separates target druggability from anti-fibrotic efficacy, which makes the key failure mode visible.
Counter evidence: The prediction would be stronger if it named specific diseases, doses, time windows, and primary endpoints.; Without a predefined fibrosis endpoint, weak biomarker shifts could be overread as support.
Reasoning tree
Public endorsements
No public quotes, records, or publications were provided for this person. On this evidence, there is no basis to say they endorsed, mentioned, or contradicted the PAI-1 inhibition fibrosis theory.
The evidence does not tie this founder to any public statement about PAI-1 inhibition or fibrosis. The three quote records point to different Daniel A. individuals in university leadership, aging research, and drug-pricing work, and none mentions MDI's fibrosis theory. One company-related publication on MDI-2517 appears in the dossier, but this record does not identify Daniel A. as an author or speaker, so it is not enough to treat as his public endorsement.
The dossier ties Daniel A. Lawrence closely to MDI's fibrosis program: he is a founder, an inventor on MDI-2268 patents, and holds equity in MDI. MDI is described publicly as developing serpin-based therapies for fibrotic disease. That supports involvement, but the evidence here does not show a public statement from Lawrence explicitly endorsing, explaining, or disputing the specific theory that PAI-1 inhibition is an anti-fibrotic mechanism.
Evidence publication IDs: 87b405f7-6850-47c3-a196-228a00eb9d0d
The evidence here supports the company theory in general, but it does not publicly tie Dinesh Khanna to that claim. There are no quotes, no public records, and no authorship or statement from him in the provided publication metadata, so we cannot say he endorsed or even mentioned it.
There is no public evidence here. The dossier includes no quotes, records, or publications tying Gillian Dines to this PAI-1 anti-fibrosis theory, so the defensible call is silence rather than endorsement, mention, or contradiction.